Ironwood Pharmaceuticals Inc
NASDAQ: IRWD · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Ironwood Pharmaceuticals Inc (IRWD) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-33.53M | $-6.76M | $-28.20M | $-4.00M | $-67.90M | $-75.24M | $-69.63M | $-273.36M | $-155.57M | $-106.93M | $-25.43M | $-99.56M | $-70.88M | $10.72M | $168.84M | $261.89M | $273.76M | $183.43M | $103.55M | $127.04M |
| Capital expenditures | $2.82M | $2.65M | $22.93M | $4.04M | $17.22M | $9.68M | $13.98M | $9.59M | $3.54M | $4.05M | $104.21M | $4.21M | $8.62M | $7.19M | $1.84M | $265000.00 | $136000.00 | $273000.00 | $142000.00 | $34000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $1.15M | $2.79M | $5.24M | $7.50M | $11.73M | $17.57M | $19.83M | $26.18M | $25.47M | $29.22M | $33.82M | $43.98M | $31.28M | $31.18M | $22.28M | $27.05M | $32.01M | $29.85M | $17.25M |
| Free cash flow | $-36.35M | $-9.41M | $-51.13M | $-8.04M | $-85.12M | $-84.92M | $-83.61M | $-282.95M | $-159.11M | $-110.98M | $-129.64M | $-103.77M | $-79.50M | $3.54M | $166.99M | $261.63M | $273.63M | $183.15M | $103.41M | $127.01M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | $111.16M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $42.96M | $49.42M | $-61.21M | $-1.19M | $186.99M | $-207.28M | $71.73M | $48.06M | $-1.60M | $185.54M | $257.08M | $36.07M | — | — | — |
Frequently asked questions
What is Ironwood Pharmaceuticals Inc's revenue?
Ironwood Pharmaceuticals Inc's trailing twelve-month revenue is $361.51M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is IRWD?
In its most recent fiscal year, IRWD ran a gross margin of 100.00%, an operating margin of 40.10%, and a net margin of 8.11%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does IRWD generate?
IRWD produced $127.01M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is IRWD's balance sheet healthy?
IRWD holds $215.46M in cash and equivalents against $385.00M in long-term debt, on $-261.83M of shareholder equity. That debt is best read against the cash flow the business throws off each year.